SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

Fueled by news of biometric software deployments at international airports, BigBear.ai is trending as chatter around potential short squeeze and new contracts intensifies. The community draws $PLTR comparisons and anticipates a breakout, while highlighting the company&#39;s AI-driven security solutions. Bullish sentiment focuses on chart setups and the potential for significant gains.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

The $BYTE.X community is rallying around this self-proclaimed 'chosen one' meme coin, touting it as the 'future of AI'. Discussion centers on its strong community, potential for high growth, and association with the AI narrative, specifically as an 'AI dog' token.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community anticipates upcoming news and partnerships, fueled by a teaser video hinting at NBA/NHL integrations. Discussions revolve around Zebec's potential in sports betting and its positioning for mainstream adoption through regulatory compliance. Community members are actively accumulating and staking ZBCN, drawing comparisons to other successful cryptos and speculating on future exchange listings.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around an upcoming token burn at 2000 watchers, anticipating it will drive up the token's value. Community members highlight the developer's active involvement and look forward to a second CEX listing on BiFinance. Despite some dips, the community remains bullish, emphasizing the project's resilience and continued growth.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the market continues its rally, with community members debating whether the Fed's upcoming rate decision will fuel further gains or trigger a "sell the news" event.  Bullish sentiment is fueled by hopes for rate cuts and potential deals, while bears point to overbought conditions and stretched valuations. Discussions include the influence of AI and potential market manipulation.

Swell

SWELL.X is trending as the community anticipates a pump, citing its low market cap and potential for high gains, drawing comparisons to other recently successful tokens. Traders are actively discussing strategies to increase volume and push the price towards targets like 25 cents, while emphasizing its listing on Coinbase. Some users highlight its utility and staking options, suggesting it's undervalued compared to other crypto assets.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending due to excitement surrounding its potential role in powering AI data centers with clean nuclear energy, fueled by a recent analyst upgrade and a new fuel recycling facility announcement. The community is actively debating the company's high valuation relative to its pre-revenue status, with some seeing significant long-term growth potential and others warning of speculative risks and an impending correction. Discussions also involve comparisons to other nuclear energy companies and the broader implications of increased uranium consumption.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape ($QS) is trending as the community discusses the company's solid-state battery technology and its potential impact on the EV sector. Recent buzz surrounds the company's presence at IAA and excitement around potential partnerships, particularly with major automakers like Volkswagen, Porsche, and Audi. Bullish sentiment is fueled by speculation of upcoming news and the anticipation of the stock breaking through resistance levels.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is trending as discussions revolve around the recent closing of a significant offering and its potential implications, with community members speculating about upcoming catalysts, including a possible reveal at the META Connect event and a potential deal with META for their smart glasses. Some traders are pointing to increasing borrow fees and anticipating a short squeeze, while others express skepticism about the company's revenue and cash burn rate. The community is weighing the possibilities of new partnerships or acquisitions amid ongoing speculation around the company's next strategic move.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Traders are closely watching UBER as it flirts with all-time highs, with the community eyeing the $100 mark as a key level to break. Recent news of Uber expanding into the train industry has generated buzz, though some are wary of the stock's reaction to positive catalysts. Community members are also discussing the stock's addition to the S&P 100, a potential influx of buying pressure from indexes, and a potential short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of genetics research company 23andMe Holding Co, which recently filed for bankruptcy, notched its best session ever on Thursday after obtaining a legal nod to start an asset sale.Late on Wednesday, 23andMe said it had secured a U.S. bankruptcy court approval for its initial Chapter 11 motions, including wage payments, vendor compensation, and a $35-million debtor-in-possession financing agreement with JMB Capital Partners.&nbsp;The court also authorized a sale process for most of its assets, requiring buyers to adhere to 23andMe's consumer privacy policies.&nbsp;The company, working with Moelis, will solicit bids over 45 days. A second hearing on further relief, including final approval of the financing facility, is set for April 22.The news sent 23andMe's stock soaring more than 45% on Thursday, although it slid in after-hours trading.On Stocktwits, message volume about 23andMe has surged by over 26,000%, while its following has grown by 4% since the company filed for bankruptcy during the weekend.Sentiment on the platform shifted from 'bearish' to 'extremely bullish' in a day.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/ME_sentiment_and_message_volume_as_of_March_27_png_50af800a78.webp" alt="ME sentiment and message volume as of March 27.png" width="1318" height="302"><figcaption>ME sentiment and message volume as of March 27. | source: Stocktwits</figcaption></figure>Retail investors speculated on potential buyouts, including one from co-founder Anne Wojcicki, who stepped down as CEO after the bankruptcy filing to pursue a takeover as "an independent bidder."One user estimated the company's genetic data alone could be worth over $1 billion, suggesting a buyout in the "$3-$5 range”&nbsp;per share.They also argued that even at a lowball valuation of $10 per user, the company could still be worth $100 million after debt, making it an attractive acquisition target.<stembedurl>https://stocktwits.com/SWIMHOLE/message/609440102</stembedurl>Another saw a Wojcicki buyout as unlikely and speculated that Big Pharma, international buyers, or even Chinese biotech firm BGI could become potential acquirers.<stembedurl>https://stocktwits.com/Jack_du/message/609505055</stembedurl>Retail investors also cited a media&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thetimes.com/business-money/companies/article/british-investor-backs-rescue-of-failing-genetics-firm-23andme-swl58rsqs">report</a> about Richard Magides, the director of Singapore-based Zentree Investment and 23andMe's second-largest shareholder, expressing interest in backing a rescue effort."We believe this business is not only salvageable but could be worth over a billion dollars if the right changes are made," he reportedly said.23andMe, founded in 2006 by Wojcicki, Linda Avey, and Paul Cusenza, quickly became one of the hottest biotech startups with its DNA testing services that let users explore their ancestry and genetic traits through simple "spit kits" mailed to their homes.The company went public via a blank-check merger in 2021, at the height of the COVID-19 pandemic, reaching a peak market capitalization of $6 billion.&nbsp;However, by 2024, its valuation had plummeted to just $120 million as it struggled to churn a profit despite amassing a customer base of 15 million.Following its bankruptcy filing, 23andMe's login portal crashed Monday evening as users rushed to delete their genetic data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A view of 23andMe headquarters in Sunnyvale, California, United States on March 25, 2025. (Photo by Tayfun Coskun/Anadolu via Getty Images)

Lifeline For 23andMe? Stock Jumps After Court Greenlights Bankruptcy Asset Sale, Retail Weighs Possible Rescue Deals

Stocktwits users spotted a media report about Richard Magides, the director of Singapore-based Zentree Investment and 23andMe's second-largest shareholder, expressing interest in backing a rescue effort.

Equity

Stocktwits users spotted a media report about Richard Magides, the director of Singapore-based Zentree Investment and 23andMe's second-largest shareholder, expressing interest in backing a rescue effort.


Tonix Pharmaceuticals saw its shares swing wildly between gains and losses on Wednesday morning as they started to trade following a 1-for-100 reverse stock split announced at the start of this week.&nbsp;The move aims to meet the Nasdaq's $1.00 minimum bid price requirement for continued listing.On Stocktwits, Tonix emerged as the most active biotech stock by message volume over the past 24 hours, but sentiment shifted from 'bullish' to 'neutral.'&nbsp;One popular post highlighted legal concerns, with the user accusing Tonix of manipulative practices such as "multiple RS [reverse stock splits] in a short time frame" and "lack of disclosures."A more optimistic user pointed to the Prescription Drug User Fee Act (PDUFA) goal date of Aug. 15, 2025, for FDA approval of Tonix's TNX-102 SL to treat fibromyalgia and the company's $10 million stock buyback announced in September as positive signs.<stembedurl>https://stocktwits.com/Camlandia/message/602920803</stembedurl><stembedurl>https://stocktwits.com/WARBUD/message/602912879</stembedurl>Tonix has reportedly executed multiple reverse stock splits in recent years, including in June 2024, May 2023, and May 2022, signaling a pattern of trying to maintain a minimum share price.&nbsp;The company's portfolio is focused on central nervous system disorders,&nbsp;prioritizing advancing TNX-102 SL.In December, the FDA&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/tnxp-stocktwits-chatter-explodes-after-fda-nod-for-nda/cJaVYSzR1F">accepted</a> the New Drug Application (NDA) for TNX-102 SL for fibromyalgia, which is also under a separate study for acute stress reaction and acute stress disorder.Earlier in 2024, Tonix reaffirmed its commitment to developing a&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/tnxp-stocktwits-chatter-explodes-after-fda-nod-for-nda/cJaVYSzR1F">mpox</a> vaccine, signaling its diversified approach to product development.Short interest in the stock has grown steadily since mid-December, rising from 0.9% to 8.5% by the end of January, according to Koyfin data.&nbsp;However, retail interest has also surged over the last three months, with Stocktwits message volume increasing by 1,750% and following jumping by nearly 10%.&nbsp;During that period, Tonix's stock price has gained more than 5%, although it has lost nearly 98% of its value over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Tonix Pharma Dominates Retail Biotech Buzz After 1-for-100 Reverse Split, Sentiment Turns Neutral Amid Volatility 

Short interest in the stock has grown steadily since mid-December, rising from 0.9% to 8.5% by the end of January, according to Koyfin data. 

Shares of NRx Pharmaceuticals Inc. surged nearly 25% on Tuesday, its best session in&nbsp;almost three weeks, drawing heavy interest from retail traders.The surge followed news of a $27 million funding deal to fund the company’s planned purchase of Hope clinics.NRx’s Hope Therapeutics unit announced a stock purchase agreement with Smith &amp; Sauer, a private investment firm specializing in healthcare and technology investments.&nbsp;The agreement includes an immediate $2 million investment in NRx common stock and a $25 million purchase of Hope’s Series A preferred shares, with $6.75 million due by Feb. 7 and the remainder by April 1.&nbsp;The funds will be used to expand Interventional Psychiatry Clinics focused on treating severe depression and other psychological disorders.Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold.&nbsp;He added that the company had initiated a financial advisory relationship to raise an additional $400 million for broader expansion.&nbsp;"Psychedelic Medications such as ketamine, neuromodulation technologies such as TMS, and digital therapeutics have sparked a revolution in psychiatry where for the first time patients with life threatening conditions such as depression and PTSD hope for a brighter future,” he said.Retail traders on Stocktwits took note, with message volume surging 94% on Tuesday and remaining at high levels ahead of Wednesday’s market open.&nbsp;Sentiment on the stock turned ‘bullish,’ with investors speculating on the impact of the projected $100 million revenue on earnings and share price.&nbsp;One user even predicted that the stock could more than double from current levels.<stembedurl>https://stocktwits.com/jonny80s/message/601877421</stembedurl><stembedurl>https://stocktwits.com/TheRealBomb/message/601781798</stembedurl>Despite losing 11% in value over the past year, NRx Pharmaceuticals has seen a 177% gain in the past three months, driven by increasing retail interest.&nbsp;The company’s follower count on Stocktwits has risen 3% over the last 12 months, while message volume has jumped 188%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding 

Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold. 

BeiGene (<a class="mention" data-mention="$BGNE" data-symbol-id="BGNE" href="https://stocktwits.com/symbol/BGNE" target="_blank">$BGNE</a>) shares jumped over 5% pre-market Wednesday, with the oncology company’s stock poised to reach a two-week high after the European Commission approved its drug Tevimbra (Tislelizumab) for first-line treatment of gastric and esophageal cancers.The approval allows Tevimbra, in combination with chemotherapy, to treat esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction adenocarcinoma.&nbsp;Clinical trial data showed that Tevimbra improved median overall survival to 17.2 months versus 10.6 months with chemotherapy alone, demonstrating statistically significant and clinically meaningful benefits.Mark Lanasa, Chief Medical Officer for Solid Tumors at BeiGene, emphasized Tevimbra’s role as the cornerstone of the company’s solid tumor portfolio, noting that more than 1.3 million patients worldwide have been treated with the drug.&nbsp;The latest approval adds to BeiGene’s momentum, marking six EU indications granted in just over a year.Esophageal cancer, which accounts for over 90% of esophageal squamous cell carcinoma cases, is one of the deadliest cancers. Beigene says it is projected to increase by nearly 60% to 957,000 annual cases by 2040, highlighting the urgent need for better treatment options.BeiGene has been expanding rapidly, recently reporting $1 billion in quarterly revenue, driven by U.S. and European product sales, and opening an $800 million R&amp;D and manufacturing facility in New Jersey.&nbsp;The company had also announced plans to rebrand as “BeOne Medicines Ltd.” and change its ticker to “ONC” following shareholder approval, signaling its commitment to global oncology leadership.<figure class="image"><a href="https://stocktwits.com/symbol/BGNE"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BGNE_sentiment_and_message_volume_Nov_27_premarket_749418ab8f.png" alt="BGNE sentiment and message volume Nov 27 premarket.png" width="1318" height="318"></a><figcaption>BGNE sentiment and message volume Nov 27 premarket as of 7:30 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment shifted from ‘neutral’ to ‘extremely bullish’ early on Wednesday following the approval news, accompanied by a surge in message volume.&nbsp;TD Cowen recently reiterated a ‘Buy’ rating on BeiGene and raised its price target to $260, citing the company’s robust pipeline, which it described as among the best in biotech.BeiGene stock has gained more than 8% year-to-date.For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aspi-stock-slides-after-fuzzy-panda-short-call/cJIWDFNRWc">ASP Isotopes Stock Fizzles After Fuzzy Panda Short Call: Retail Eyes Opportunity</a>

Clinical trial data showed that Tevimbra improved median overall survival to 17.2 months versus 10.6 months with chemotherapy alone.

BeiGene Stock Eyes 2-Week High After EU Approves Cancer Treatment: Retail Enthusiasm Grows

The latest approval adds to BeiGene’s momentum, marking six EU indications granted in just over a year.

Palumbo Wealth Management LLC Makes New $228,000 Investment in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)

Palumbo Wealth Management LLC acquired a new position in shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Free Report) in the fourth quarter, according to its most recent disclosure with...

ProShares Ultra Nasdaq Biotechnology (BIB, $56.85) Stochastic Oscillator left the overbought zone on April 01, 2024

This is a signal that BIB's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

ProShares Ultra Nasdaq Biotechnology (BIB, $56.85) Aroon Indicator entered a Downtrend on April 01, 2024.

For the last three days, A.I.dvisor has detected that BIB's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Update

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB  Get Free Report) was the recipient of a large growth in short interest in March. As of March 15th, there was short interest totalling 55,700...

ProShares Ultra Nasdaq Biotechnology (BIB, $57.54) entered Uptrend as Momentum indicator ascends above 0 level on Mar 28, 2024

This indicator may be signaling BIB's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

ProShares Ultra Nasdaq Biotechnology (BIB, $57.54) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 28, 2024

This is a Bullish indicator signaling BIB's price could rise from here. Traders may explore going long the stock or buying call options...

ProShares Trust - ProShares Ultra Nasdaq Biotechnology 2X Shares

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

BIB
ProShares Ultra Nasdaq Biotechnology

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest BIB News

BIB ProShares Ultra Nasdaq Biotechnology